Chemotherapy in hormone-refractory prostate cancer.
Research in the past 3 decades has resulted in new approaches to treat patients with hormone-refractory prostate cancer. Employing the new treatment options, we are now able to prolong survival in these patients. At present, docetaxel given on a 3-week schedule is the standard of care for patients with hormone-refractory prostate cancer. Several new treatments are under investigation in phase III trials and will further improve the treatment options for these patients within the next years.